KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.

Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Chern-En Chiang, Gerard C M Linssen, Clara I Saldarriaga, Jose F K Saraiva, Naoki Sato, Morten Schou, Dirk von Lewinski, James Lay-Flurrie, Andrea Scalise, Katja Rohwedder, Akshay S Desai, Carolyn S P Lam, Michele Senni, Sanjiv J Shah, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D Solomon, John J V McMurray

JAMA Cardiol 10(8) 829-840

PMID40531488
PMCIDPMC12177723
DOI10.1001/jamacardio.2025.1775
发表日期2025-06-18
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Patients with frailty are often perceived to have a less favorable benefit-risk profile for novel therapies and therefore may be less likely to receive these. OBJECTIVE: To examine the efficacy and safety of finerenone, compared with placebo, according to frailty status in patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or with HF and preserved ejection fraction (HFpEF). DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of a phase 3 randomized clinical trial, the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF), conducted across 653 sites in 37 countries. Patients with HF with New York Heart Association functional class II through IV, a left ventricular ejection fraction of 40% or higher, evidence of structural heart disease, and elevated natriuretic peptide levels were randomized between September 2020 and January 2023. Data analysis was conducted from October 1 to November 30, 2024. INTERVENTION: Addition of once-daily finerenone or placebo to usual therapy. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death and total worsening HF events. Frailty was measured using the Rockwood cumulative deficit approach. RESULTS: Of the 6001 patients randomized in FINEARTS-HF, a frailty index (FI) was calculable in 5952 patients (mean [SD] age, 72.0 [9.6] years; 3241 [54.4%] male). In total, 1588 patients (26.7%) had class I frailty (FI ≤0.210 [not frail]), 2141 (36.0%) had class II frailty (FI 0.211-0.310 [more frail]), and 2223 (37.3%) had class III frailty (FI ≥0.311 [most frail]). Compared with patients with class I frailty, those with class II and III frailty had a higher risk of the primary outcome (unadjusted rate ratio [RR], 1.88 [95% CI, 1.54-2.28] for class II and 3.86 [95% CI, 3.22-4.64] for class III). The effect of finerenone on the primary outcome did not vary significantly by frailty class (class I: RR, 1.07 [95% CI, 0.77-1.49]; class II: RR, 0.66 [95% CI, 0.52-0.83]; class III: RR, 0.91 [95% CI, 0.76-1.07]; P for interaction = .77). Frailty class did not modify the effects of finerenone on the components of the primary outcome, all-cause death, or improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score. The effects of finerenone, compared with placebo, on experiencing hypotension, elevated creatinine level, hyperkalemia, or hypokalemia did not differ by frailty class. CONCLUSIONS AND RELEVANCE: In FINEARTS-HF, finerenone reduced the risk of total worsening HF events and cardiovascular death, and it improved symptoms; these effects were not modified by frailty status. In addition, the effects of finerenone on experiencing hypotension, elevated creatinine level, hyperkalemia, or hypokalemia did not differ by frailty status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 1

Figure 1.. Outcomes According to Frailty Index (FI) Class The cumulative hazard for the primary composite outcome of cardiovascular death and total worsening heart failure (HF) events (A) and total worsening HF events (B) and the cumulative incidence for cardiovascular death (C) and all-cause death (D) are shown.

A

cardiovascular death and total worsening HF events

Figure 1 · Panel A

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

total worsening HF events

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

cardiovascular death

Figure 1 · Panel C

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

all-cause death

Figure 1 · Panel D

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2.. Effects of Finerenone Compared With Placebo on the Primary Composite Outcome and Total Worsening Heart Failure (HF) Events According to Frailty Index The association between frailty index and the incidence rate for the primary composite outcome of cardiovascular death and total worsening HF events (A) and total worsening HF events (B) is shown, and the absolute benefit of finerenone across the range of frailty index for the primary composite outcome of cardiovascular death and total worsening HF events (C) and total worsening HF events (D) is shown. The shaded areas represent the 95% CIs.
非 KM Figure